INTRODUCTION: Sympathetic activity plays an important role in the pathogenesis of ventricular tachyarrhythmia. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension, proved to reduce local and whole-body sympathetic activity. METHODS: Two patients with chronic heart failure (CHF) (non-obstructive hypertrophic and dilated cardiomyopathy, NYHA III) suffering from therapy resistant electrical storm underwent therapeutic renal denervation. In both patients, RDN was conducted with agreement of the local ethics committee and after obtaining informed consent. RESULTS: The patient with hypertrophic cardiomyopathy had recurrent monomorphic ventricular tachycardia despite extensive antiarrhythmic therapy, following repeated endocardial and epicardial electrophysiological ablation attempts to destroy an arrhythmogenic intramural focus in the left ventricle. The second patient, with dilated nonischemic cardiomyopathy, suffered from recurrent episodes of polymorphic ventricular tachycardia and ventricular fibrillation. The patient declined catheter ablation of these tachycardias. In both patients, RDN was performed without procedure-related complications. Following RDN, ventricular tachyarrhythmias were significantly reduced in both patients. Blood pressure and clinical status remained stable during the procedure and follow-up in these patients with CHF. CONCLUSION: Our findings suggest that RDN is feasible even in cardiac unstable patients. Randomized controlled trials are urgently needed to study the effects of RD in patients with electrical storm and CHF.
INTRODUCTION: Sympathetic activity plays an important role in the pathogenesis of ventricular tachyarrhythmia. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension, proved to reduce local and whole-body sympathetic activity. METHODS: Two patients with chronic heart failure (CHF) (non-obstructive hypertrophic and dilated cardiomyopathy, NYHA III) suffering from therapy resistant electrical storm underwent therapeutic renal denervation. In both patients, RDN was conducted with agreement of the local ethics committee and after obtaining informed consent. RESULTS: The patient with hypertrophic cardiomyopathy had recurrent monomorphic ventricular tachycardia despite extensive antiarrhythmic therapy, following repeated endocardial and epicardial electrophysiological ablation attempts to destroy an arrhythmogenic intramural focus in the left ventricle. The second patient, with dilated nonischemic cardiomyopathy, suffered from recurrent episodes of polymorphic ventricular tachycardia and ventricular fibrillation. The patient declined catheter ablation of these tachycardias. In both patients, RDN was performed without procedure-related complications. Following RDN, ventricular tachyarrhythmias were significantly reduced in both patients. Blood pressure and clinical status remained stable during the procedure and follow-up in these patients with CHF. CONCLUSION: Our findings suggest that RDN is feasible even in cardiac unstable patients. Randomized controlled trials are urgently needed to study the effects of RD in patients with electrical storm and CHF.
Authors: Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm Journal: Lancet Date: 2010-11-17 Impact factor: 79.321
Authors: Christian Ukena; Felix Mahfoud; Ingrid Kindermann; Christine Barth; Matthias Lenski; Michael Kindermann; Mathias C Brandt; Uta C Hoppe; Henry Krum; Murray Esler; Paul A Sobotka; Michael Böhm Journal: J Am Coll Cardiol Date: 2011-09-06 Impact factor: 24.094
Authors: Peter J Schwartz; Silvia G Priori; Marina Cerrone; Carla Spazzolini; Attilio Odero; Carlo Napolitano; Raffaella Bloise; Gaetano M De Ferrari; Catherine Klersy; Arthur J Moss; Wojciech Zareba; Jennifer L Robinson; W Jackson Hall; Paul A Brink; Lauri Toivonen; Andrew E Epstein; Cuilan Li; Dayi Hu Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Arthur A M Wilde; Zahurul A Bhuiyan; Lia Crotti; Mario Facchini; Gaetano M De Ferrari; Thomas Paul; Chiara Ferrandi; Dave R Koolbergen; Attilio Odero; Peter J Schwartz Journal: N Engl J Med Date: 2008-05-08 Impact factor: 91.245
Authors: Paul A Sobotka; Felix Mahfoud; Markus P Schlaich; Uta C Hoppe; Michael Böhm; Henry Krum Journal: Clin Res Cardiol Date: 2011-06-19 Impact factor: 5.460
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Dominik Linz; Arne van Hunnik; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Stephan H Schirmer; Matthias Lenski; Hans-Ruprecht Neuberger; Ulrich Schotten; Michael Böhm Journal: Clin Res Cardiol Date: 2014-03-29 Impact factor: 5.460
Authors: Britta Vogel; Michael Kirchberger; Martin Zeier; Felicitas Stoll; Benjamin Meder; Daniel Saure; Martin Andrassy; Oliver J Mueller; Stefan Hardt; Vedat Schwenger; Anna Strothmeyer; Hugo A Katus; Erwin Blessing Journal: Clin Res Cardiol Date: 2013-10-15 Impact factor: 5.460
Authors: Hitesh C Patel; Paramdeep S Dhillon; Felix Mahfoud; Alistair C Lindsay; Carl Hayward; Sabine Ernst; Alexander R Lyon; Stuart D Rosen; Carlo di Mario Journal: Clin Res Cardiol Date: 2014-05 Impact factor: 5.460
Authors: Wolfram C Poller; Henryk Dreger; Marius Schwerg; Hansjürgen Bondke; Christoph Melzer Journal: Clin Res Cardiol Date: 2014-01-28 Impact factor: 5.460